Zymergen, a biotech company that manufactures materials from genetically altered microbes, has raised $130 million in Series B funding led by SoftBank. The company's products have broad applications across industries such as chemicals & materials, agriculture and healthcare.
Founded in 2013, Zymergen has raised about $176 million in total funding, including a $44 million Series A last June at a $104 million valuation. As part of the most recent financing, Deep Nishar, managing director at SoftBank, is joining the company's board, as is former US Secretary of Energy Steven Chu. Other participating Series B investors include AME Cloud Ventures, Data Collective, DFJ, Obvious Ventures and True Ventures.